SCHEMBL15048962

SCHEMBL15048962

CCOC(=O)c1sc(-c2cccc(F)c2)nc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 14/20 1.00
MAPT P10636 3/20 0.73
MEN1 O00255 2/20 0.73
KMT2A Q03164 2/20 0.73
CDC7 O00311 4/20 0.73
DBF4 Q9UBU7 4/20 0.73
KDM4E B2RXH2 1/20 0.62
HSP90AA1 P07900 1/20 0.62
CRHBP P24387 1/20 0.62
CRHR2 Q13324 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15049177 0.86 TRPM8 (0.76) TRPM8MAPTMEN1KMT2ACDC7
SCHEMBL17374877 0.86 TRPM8 (0.75) TRPM8MAPTMEN1KMT2ACDC7
SCHEMBL8867589 0.85 TRPM8 (1.00) TRPM8MAPTMEN1KMT2ACDC7
SCHEMBL15049120 0.85 TRPM8 (0.74) TRPM8MAPTMEN1KMT2ACDC7
SCHEMBL28245760 0.85 TRPM8 (0.73) TRPM8MAPTMEN1KMT2ACDC7
SCHEMBL15049096 0.85 TRPM8 (1.00) TRPM8MAPTMEN1KMT2ACDC7
SCHEMBL6338322 0.84 TRPM8 (1.00) TRPM8MAPTMEN1KMT2ACDC7
SCHEMBL17374866 0.84 TRPM8 (1.00) TRPM8MAPTMEN1KMT2A
SCHEMBL15049591 0.83 TRPM8 (0.71) TRPM8MAPTMEN1KMT2ACDC7
SCHEMBL17317910 0.83 TRPM8 (0.71) TRPM8MAPTMEN1KMT2ACDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2793883-B1 TRPM8 ANTAGONISTS DOMPE FARM SPA (IT) 2018-04-18 EP claimed
US-9856246-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2018-01-02 US claimed
US-20170129881-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-05-11 US claimed
US-9585875-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-03-07 US claimed
US-20140371276-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2014-12-18 US claimed
EP-2793883-A1 TRPM8 ANTAGONISTS Dompe' S.p.A. (IT) 2014-10-29 EP claimed
WO-2013092711-A1 TRPM8 ANTAGONISTS DOMPE' S.P.A. (IT) 2013-06-27 WO claimed
EP-2606888-A1 Trpm8 antagonists Dompe' S.P.A. (IT) 2013-06-26 EP claimed
CN-108699053-B 4-hydroxy-2-phenyl-1, 3-thiazol-5-yl methanone derivatives as TRPM8 antagonists 东佩制药股份公司 2022-01-14 CN disclosed
US-11046662-B2 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as TRPM8-inhibitors in treatment of neuralgia, pain, COPD and asthma DOMPÉ FARMACEUTICI S.P.A. (IT) 2021-06-29 US disclosed
CN-106660975-B 2-aryl-4-hydroxy-1, 3-thiazole derivatives as TRPM 8-inhibitors for the treatment of neuralgia, pain, COPD and asthma 东佩制药股份公司 2019-12-31 CN disclosed
EP-3394053-B1 (4-HYDROXY-2-PHENYL-1,3-THIAZOL-5-YL) METHANONE DERIVATIVES AS TRPM8 ANTAGONISTS DOMPE FARM SPA (IT) 2019-08-21 EP disclosed
US-20190106395-A1 2-ARYL-4-HYDROXY-1,3-THIAZOLE DERIVATIVES USEFUL AS TRPM8-INHIBITORS IN TREATMENT OF NEURALGIA, PAIN, COPD AND ASTHMA DOMPÉ FARMACEUTICI S.P.A. (IT) 2019-04-11 US disclosed
US-10246448-B2 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2019-04-02 US disclosed
WO-2015197640-A1 2-ARYL-4-HYDROXY-1,3-THIAZOLE DERIVATIVES USEFUL AS TRPM8-INHIBITORS IN TREATMENT OF NEURALGIA, PAIN, COPD AND ASTHMA DOMPE' FARMACEUTICI S.P.A. (IT) 2015-12-30 WO disclosed
US-20140371276-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2014-12-18 US disclosed
CN-104220069-A Trpm8 antagonists DOMPE SPA 2014-12-17 CN disclosed
EP-2793883-A1 TRPM8 ANTAGONISTS Dompe' S.p.A. (IT) 2014-10-29 EP disclosed
WO-2013092711-A1 TRPM8 ANTAGONISTS DOMPE' S.P.A. (IT) 2013-06-27 WO disclosed
EP-2606888-A1 Trpm8 antagonists Dompe' S.P.A. (IT) 2013-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170129881-A1 TRPM8 ANTAGONISTS TRPM8, TRPM7, TRPM5 TRPM8 1/4885MAPT 282/4885MEN1 1269/4885
US-20140371276-A1 TRPM8 ANTAGONISTS TRPM8, TRPM7, TRPV1 TRPM8 1/4885MAPT 293/4885MEN1 1013/4885
US-20190106395-A1 2-ARYL-4-HYDROXY-1,3-THIAZOLE DERIVATIVES USEFUL AS TRPM8-INHIBITORS IN TREATMENT OF NEURALGIA, PAIN, COPD AND ASTHMA TRPM8, TRPV1, TRPM7 TRPM8 1/4885MAPT 468/4885MEN1 2385/4885
US-11046662-B2 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as TRPM8-inhibitors in treatment of neuralgia, pain, COPD and asthma TRPM8, TRPV1, TRPM7 TRPM8 1/4885MAPT 468/4885MEN1 2692/4885
US-10246448-B2 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as TRPM8 antagonists TRPM8, TRPM5, TRPM4 TRPM8 1/4885MAPT 608/4885MEN1 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.